Elixira

Elixira was invented and founded by Tess Fries, an independent innovator developing next-generation, patent-pending biomedical technologies. Elixira is an AI-guided nanobot platform engineered as a one-time injection for lifelong, autonomous prevention across all cancer types. Its technical feasibility has been independently confirmed by a leading Contract Research Organization (CRO), and all core technologies underlying Elixira have been peer-reviewed and validated. A full feasibility report is available to prospective partners under NDA. In parallel to Elixira, Tess is also the creator of Predictive Bioharmonics (PB) — a universal dynamical-systems framework developed entirely by her. Tess has recently extended PB into IVF embryo stability analysis, enabling non-invasive prediction of embryonic viability using harmonic drift thresholds and universal stability metrics. PB is now available for pilot collaboration with IVF clinics worldwide. General inquiries: contact@elixira.tech Licensing inquiries: licensing@elixira.tech